Pfizer Discontinues Once-Daily Weight Loss Pill Over Liver Injury In One Patient

Pfizer Inc. (NYSE:PFE) is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (PF-06882961) met key pharmacokinetic objectives. The study confirmed a formulation and dose that could deliver a competitive efficacy and tolerability profile in Phase 3 testing based on earlier studies of twice-daily danuglipron.

The stopped trials include:

Phase 1, open-label study to evaluate the multiple-dose pharmacokinetics of danuglipron following oral administration in otherwise healthy adult participants with overweight or obesity.

A two-part phase 1, open-label, fixed-sequence study to evaluate the multiple-dose pharmacokinetics of danuglipron following oral administration and the effects of steady-state danuglipron on the pharmacokinetics of single oral dose of atorvastatin and rosuvastatin in otherwise healthy adult participants with overweight or obesity.

Also Read: Benzinga Bulls And Bears: Apple, Nike, US Steel ...

https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient